PCSK9 Forum
Click here to forward this email to a colleague
Facebook Twitter RSS YouTube linkedin
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact
6th Closed Meeting of PCSK9 Forum Editorial Board, 
Prague, Czech Republic
Looking to 2017 European Society of Cardiology Congress, Barcelona, Spain


Positive topline results from the REVEAL trial with anacetrapib, a cholesteryl ester transfer protein inhibitor, and the CANTOS trial with canakinumab, an interleukin-1β inhibitor, have fuelled expert debate about the future management of residual vascular risk.

New PCSK9 Forum Associate Editor, Professor Anthony Wierzbicki discusses what these findings could mean for the management of high risk patients.

Read the report and watch the video »

Visit the Forum at www.pcsk9forum.org for the full results to be presented in Barcelona this summer.
Check back for the latest news and views about PCSK9 science and translation to the clinic
Like us on Facebook
For the latest updates, PCSK9 news and analysis.
Follow us on Twitter
Hot topics, news and conference reports.
YouTube Channel
For videos, interviews and webcasts from leading experts.
Our popular therapeutic guide

Read online & download second edition now »

Register now at www.pcsk9forum.org to receive the updated third edition e-book with post ACC17 content including the FOURIER trial.
New eBook
Questions & Answers

Why are new treatments needed?

Read the full answer and other questions on the PCSK9 Forum »
Educational Partners
and Supporters
Amgen The Medicines Company pFizer Sanofi
Copyright PCSK9 Forum 2017. Please click here to unsubscribe from future mailings.